LEVESPY Tablet
Levetiracetam
500MG
Corel Pharmaceutical
| Pack size | |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 18.00 NPR |
Indications
LEVESPY Tablet is used for:
Partial seizures
Adult Dose
Oral
Adjunct in seizures
Adult: For partial seizures w/ or w/o secondary generalisation; myoclonic seizures (w/ juvenile myoclonic epilepsy); primary generalised tonic-clonic seizures (w/ idiopathic generalised epilepsy): Initially, 500 mg bid on the 1st day. Adjust dose in increments or decrements of 500 mg bid at 2-4 wk intervals.
Max: 1,500 mg bid.
Monotherapy for partial seizures with or without secondary generalisation
Adult: Recommended starting dose is 250 mg bid, increased to an initial therapeutic dose of 500 mg bid after 2 wk. May further increase by 250 mg bid every 2 wk depending upon response.
Max: 1,500 mg bid.
Intravenous
Adjunct in seizures
Adult: For partial seizures w/ or w/o secondary generalisation; myoclonic seizures (w/ juvenile myoclonic epilepsy); primary generalised tonic-clonic seizures (w/ idiopathic generalised epilepsy): Initially, 500 mg bid on the 1st day. Adjust dose in increments or decrements of 500 mg bid at 2-4 wk intervals.
Admin by infusion over 15 min.
Max: 1,500 mg bid. Max duration: 4 days.
Monotherapy for partial seizures with or without secondary generalisation
Adult: Recommended starting dose is 250 mg bid, increased to an initial therapeutic dose of 500 mg bid after 2 wk. May further increase by 250 mg bid every 2 wk depending upon response. Admin by infusion over 15 min.
Max: 1,500 mg bid. Max duration: 4 days.
Hepatic impairment: Severe: Reduce dose by 50%.
Child Dose
Oral
Adjunct in seizures
Child: 1 to <6 mth Initially, 14 mg/kg daily, may adjust in increments of 14 mg/kg at 2-wk intervals.
Max: 42 mg/kg daily;
>6 mth <50 kg: Initially, 20 mg/kg daily, may adjust in increments of 20 mg/kg at 2-wk intervals.
Max: 60 mg/kg daily.
Intravenous
Adjunct in seizures
Child: 1 to <6 mth Initially, 14 mg/kg daily, may adjust in increments of 14 mg/kg at 2-wk intervals.
Max: 42 mg/kg daily;
>6 mth <50 kg: Initially, 20 mg/kg daily, may adjust in increments of 20 mg/kg at 2-wk intervals.
Max: 60 mg/kg daily. To be given via infusion over 15 min.
Renal Dose
Renal impairment: ESRD patients undergoing dialysis: Loading dose of 750 mg, followed by 500-1,000 mg once daily; supplemental dose of 250-500 mg after dialysis.
CrCl (ml/min) Dosage Recommendation
<30 250-500 mg bid.
30-49 250-750 mg bid.
50-79 500-1,000 mg bid.
Administration
May be taken with or without food. Oral soln may be taken directly or diluted in a glass of water.
Contra Indications
Hypersensitivity.
Precautions
Renal and hepatic impairment; pregnancy, lactation; patients undergoing haemodialysis. If psychotic symptoms (eg hallucination) and behavioural symptoms (eg agitation, anxiety) occur, reduce dosage. Abrupt withdrawal may result in increased seizure frequency. May impair ability to drive or operate machinery during initial therapy.
Lactation: Excreted in breast milk; not recommended
Pregnancy-Lactation
Interactions
Enzyme-inducing antiepiletic drugs.
Adverse Effects
Side effects of Levetiracetam :
>10%
Asthenia (11-15%),Headache (14-19%),Infection (11-15%),Increased blood pressure (17% in children < 4 years),Somnolence (11-15%),Drowsiness (2-23%),Fatigue (10-11%),Anorexia (3-13%),Weakness (9-15%),Nasopharyngitis (7-15%),Cough (2-11%)
1-10%
Viral infection (2%),Asthma (2%),Dizziness (5-9%),Nervousness (2-10%),Amnesia (2%),Anxiety (2-3%),Ataxia (3%),Depression (2-5%),Hostility (10%),Paresthesia (2%),Sinusitis (2%),Diplopia (2%),Amblyopia (2%),Conjunctivitis (2-3%),Albuminuria (4%)
<1%
Abnormal hepatic function tests,Dyskinesia,Eczema,Neutropenia,Decreased hematocrit,Leukopenia,Suicidal tendencies,Hepatitis,Pancreatitis,Bone marrow suppression,Epidermal necrolysis
Mechanism of Action
Anticonvulsant used in the treatment of partial seizures. The precise mechanism of anticonvulsant effect is unknown.
Note
LEVESPY 500MG Tablet manufactured by Corel Pharmaceutical. Its generic name is Levetiracetam. LEVESPY is availble in Nepal.
Farmaco Nepal drug index information on LEVESPY Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.